Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study

Phase 2 Completed 46 enrolled Vanderbilt University Medical Center Massachusetts General Hospital · collab National Institute on Aging (NIA) · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This proof-of-concept study examines whether the acute brain dysfunction that occurs in critically ill patients is improved by administration of intravenous guanfacine.

Timeline

Start: 2021-05-04
Primary completion: 2024-03-30
Completion: 2025-11-30

Publications

Arnsten AFT, Ishizawa Y, Xie Z. Scientific rationale for the use of alpha2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders. Mol Psychiatry. 2023 Nov;28(11):4540-4552. doi: 10.1038/s41380-023-02057-4. Epub 2023 Apr 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Guanfacine	Small molecule	—	Intravenous

Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study

Summary

Timeline

Publications

Drugs

Indications